From: A review article of inflammatory bowel disease treatment and pharmacogenomics
Subcutaneous [12]. BIOLOGIC | Induction regimen | Maintenance dose | Maintenance interval | Escalation |
---|---|---|---|---|
Infliximab | 5Â mg at week 0 | 5Â mg/kg | Q8 | 10Â mg/kgQ8 |
OR 5Â mg/kg Q4 | ||||
Adalimumab | 160Â mg at week 0 | 40Â mg | Q2 | 80Â mg Q2 Or 40Â mg weekly |
80Â mg at week 2 | ||||
Golimumab | 200 mg at week 0 | 50 mg if > 80 kg | Q4 | IF < 80 KG Increase to 100 mg |
100 mg at week 2 | 100 mg if > 80 kg | From week 6 (if > 80 kg, N/A) | ||
Vedolizumab | 300Â mg at weeks 0, 2, & 6 | 300Â mg | Q8 | Q4 (Additional Week 10 dose in CD) |
Ustekinumab | Week 0.iv: | 90Â mg SC | Q12 OR Q8 | Q8 |
 < 55 kg 260 mg | ||||
55–85 kg 390 mg | ||||
 > 85 kg 520 mg |